In an interview with the media on the emergency use of the new crown inactivated vaccine and overseas phase III clinical research, the head of Sinopharm China Biotechnology revealed that the two new crown inactivated vaccines developed by Sinopharm China Bio have been vaccinated for hundreds of thousands of times, and none of them is obviously bad. In response, no one was infected; among them, tens of thousands of people who went to overseas high-risk countries and regions after the vaccine had no infection so far.

　　 Zhou Song, the general counsel of Sinopharm China Biotechnology, said that three domestic new crown inactivated vaccines have been approved for clinical trials, and Sinopharm China Biotechnology accounts for two of them. It is currently the largest emergency vaccination and the largest number of people. Zhou Song emphasized that the more important thing is that the emergency use of the new crown inactivated vaccine is aimed at people with high risk exposures, such as medical staff who treat people infected with the new crown virus, as well as diplomats and foreigners going to high-risk countries. Dispatch employees and Chinese-funded enterprises "Belt and Road" construction personnel and so on. These tens of thousands of people have been overseas for a few months after being vaccinated. Among them, in the areas where the epidemic broke out, some left-behind employees were infected but they did not. Parallel control data like this is available in multiple countries, which proves the effectiveness of the vaccine.

　　, Zhang Yuntao, vice president of Sinopharm China Biology, said that phase I and II clinical studies of the new crown inactivated vaccine were carried out in China, and neutralizing antibodies were produced. "Neutralizing antibody testing is the gold standard." In overseas Phase III clinical studies, neutralizing antibodies will also be continuously observed. Neutralizing antibodies are comparable. Overseas trials have expanded races, countries, and populations, and most importantly, they have been recognized overseas, which will be better for future applications.

　　 Zhang Yuntao said that in the past, it was difficult for our vaccines to be exported. There were a series of regulations and clinical restrictions. Now that our scientific and technological strength is strong, the data of phase I and II clinical trials are recognized overseas, and the direct development of phase III clinical research overseas is a model of international cooperation. In the future, if China's approval is passed, as long as these countries do clinical research, they can also be legally listed on the market. He revealed that at present, there are 500 million doses of intentional orders for the new crown inactivated vaccine in the world.

Huawei also released EMUI 11 equipped with Hongmeng distributed technology.

On September 10, during the Huawei Developer Conference 2020, Huawei officially released version 2.0 of the Hongmeng system.

Huawei Consumer Business CEO Yu Chengdong said that in December this year, the Beta version of smartphones will be released for developers, and the mobile phone version of the Hongmeng system will be released. Next year, Huawei mobile phones will fully support Hongmeng 2.0. Since then, terminal equipment such as Huawei mobile phones and tablets will be connected to the Hongmeng system one after another.

At the same time, Hongmeng System has also taken the first step to empower the third-party ecosystem, which is to integrate a series of platforms and platforms including source code, SDK, development board/module, Ark compiler, full-scene development framework, etc. The tool chain is open to hardware and software manufacturers to help developers quickly develop equipment and software based on the Hongmeng system and improve the Hongmeng ecosystem.

In terms of hardware, Hongmeng has cooperated with some home appliance manufacturers. Home appliance manufacturers including Midea and Joyoung will soon release home appliances products based on the Hongmeng system. These home appliances will be connected with the data on the mobile phone in real time to achieve synergy for consumers. Provide more personalized service.

Wang Chenglu, Huawei’s Consumer Business Software Department, stated that from September 10, the Hongmeng system will be open sourced for 128KB-128MB terminal devices such as large screens, watches, and car machines. In April 2021, it will be open sourced for memory 128MB-4GB terminal devices. After October 2010, it will be open sourced for all devices above 4GB.

In addition, Huawei also released EMUI 11 equipped with Hongmeng distributed technology. In addition to design style and interaction upgrades, EMUI 11 will no longer be limited to interactions between mobile phones, but also to realize interactions between devices equipped with the Hongmeng system, such as mobile phones and tablets, mobile phones and smart homes.

Wang Chenglu said that from September 10th, EMUI 11 will officially open Beta, and mobile phones using EMUI 11 can upgrade Hongmeng OS 2.0 in the future. Beginning next year, Huawei's mobile phones may fully enter the Hongmeng era.

　　In the first half of this year, Huawei further consolidated its position as the world's largest manufacturer of communications infrastructure equipment.

　　Statistics from the Dell'Oro Group show that after covering the mobile core network, wireless access network, broadband access, microwave and optical transmission, carrier-grade routers and customer edge switches and other communication equipment, the first half of the year ended. The revenue share is as high as 31%, an increase of 3 percentage points over the same period last year.

　　Although Nokia (after merging with Alcatel-Lucent) ranked second, its revenue market share was only 14%, a drop of 2% year-on-year.

　　 In fact, after surpassing Nokia for the first time in 2015, Huawei has been widening the gap with it. The report attributed Huawei's impressive performance to its large participation in domestic 5G construction, while Nokia has nothing worth mentioning in this market.

　　Huawei sits firmly as the world's largest communications equipment manufacturer: widening the gap with the second Nokia

　　 3~7 were Ericsson, ZTE, Cisco, Ciena, and Samsung, among which Ericsson’s share was the same as last year, at 14%. ZTE increased by two percentage points year-on-year to 11%.

　　 Of course, Huawei, Nokia, and ZTE are all involved in wireless and wired devices, Ericsson focuses on wireless devices, and Cisco and Ciena mainly focus on wired devices.

　　 If you look at the 5G equipment market alone, Huawei still ranks first with a share of 35.7%, followed by Ericsson with 24.6%, Nokia 15.8%, Samsung 13.2%, and ZTE 9.3%.

　　Huawei sits firmly as the world's largest communications equipment manufacturer: widening the gap with the second Nokia

Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State and Chairman of the Central Military Commission, awarded medals and medals to winners of the National Medal and National Honorary Titles and delivered important speeches.

Zhong Nanshan
Awarded
Medal of the Republic
Leading figures in the field of respiratory disease research in my country have the courage to speak up and take responsibility. The prevention and control strategies and measures proposed have saved countless lives and have made great contributions to the prevention and control of SARS and COVID-19.

Zhang Boli
Awarded
National honorary title of "People's Hero"
Instructing Chinese medicine to intervene in the treatment of new coronary pneumonia, presided over the research and formulation of integrated Chinese and Western medicine has become a highlight of China's plan, and has made a significant contribution to promoting the inheritance and innovation of Chinese medicine.

Zhang Dingyu
Awarded
National honorary title of "People's Hero"
An outstanding representative who has rooted in the front line of medical care, as a patient with progressive frost disease, during the epidemic, he still has no hesitation, charged forward, rescued the wounded, and made a significant contribution to winning the defense war in Hubei and Wuhan.

Chen Wei
Awarded
National honorary title of "People's Hero"
He has been engaged in research on the prevention and control of biological hazards for a long time. After the outbreak of the new crown pneumonia epidemic, he has made major achievements in basic research, vaccine and protective drug research and development, and has made major contributions to epidemic prevention and control.

The conference also commended the national advanced individual and advanced collective in the fight against the new crown pneumonia epidemic, the national outstanding communist party member, the national advanced grassroots party organization

What is the current progress of the recombinant new crown vaccine developed by the Chinese Academy of Military Sciences?
What are the characteristics of this vaccine?
After the successful phase III clinical trial, how long will it take to go public on a large scale?
Who is suitable for vaccination?
Does the vaccine have a preventive effect on the mutated new coronavirus?
What is the current position of my country's vaccine research and development in the world?

In response to these issues, a reporter from Xinhua News Agency recently interviewed Chen Wei, the winner of the national honorary title of "People's Hero", an academician of the Chinese Academy of Engineering, and a researcher at the Academy of Military Medicine of the Academy of Military Sciences.

"What are the characteristics of the recombinant new crown vaccine developed by the Academy of Military Sciences?"

Chen Wei: We have independent intellectual property rights for this vaccine, which means that we do not need to look at the faces of others to develop our vaccine at any time and on any occasion. When the subsequent vaccine is put into production and application, we can also let the Chinese people get the vaccination as soon as they need it at a lower price.

This is a technologically advanced virus vector vaccine. Its outstanding feature is that it can have both humoral immunity (antibody and neutralizing antibody) and cellular immunity. Since the virus is a parasite, it cannot grow or reproduce by itself. It needs to reproduce in human cells. Therefore, cellular immunity is essential for virus prevention and control. We launched the world's first phase I clinical trial on March 16, and published the phase I clinical trial data on the "Lancet" on May 22. All 108 people vaccinated developed antibodies. The editor-in-chief of "The Lancet" commented on this as "The vaccine is safe and well tolerated. It is the world's first clinical data. A single injection can quickly trigger immunity, which is an important milestone." In this process, we Testing methods and testing indicators have been announced to the world, so that scientific research colleagues in other countries will avoid some detours and speed up vaccine research.

On July 20th, we announced Phase II clinical data for the first time to the world. Phase I and Phase II clinical trials have proved the effectiveness and safety of the vaccine. In June, our vaccine has been vaccinated in specific populations.

Phase III clinical trials are currently being effectively advanced. As the domestic epidemic has been effectively controlled, we need to go abroad to advance Phase III clinical trials and conduct larger-scale vaccine effectiveness and safety evaluations.

"After the Phase III clinical trial is successful, how long will it take to go public on a large scale?"

Chen Wei: Generally speaking, the development of a vaccine has to go through phase three clinical trials, and the test results meet the relevant requirements before preparing for mass production. However, our recombinant COVID-19 vaccine has been prepared for large-scale mass production since the Phase I clinical trial. From the current point of view, the goal of annual output of 300 million is achievable, and we are working hard to expand production capacity. After the Phase III test results come out, our production capacity will also keep up, and we will be ready to vaccinate the people on a large scale at any time and strive for seamless integration.

"Which people do you think are suitable for priority vaccination?"

Chen Wei: First of all, people who are in direct contact with the new coronavirus or have the possibility of close contact, such as those closely related to epidemic prevention, especially front-line medical staff, virus-related researchers, and front-line customs staff. In addition, people with underlying diseases are also our focus. There are also people who are willing to vaccinate themselves.

Regarding the vaccination group and vaccination time, we only put forward opinions and suggestions, and the relevant departments make overall decisions. We mainly prepare high-quality vaccines and can use them in time when the country needs them. This is our responsibility.

"How long will the recombinant new crown vaccine provide effective protection after vaccination?"

Chen Wei: It has only been more than half a year since the new coronavirus was isolated. How long is the validity period of the vaccine? There will not be too many data in the world. It must be data within one year. Our vaccine entered the world's first phase I clinical trial in March, and we only have data within half a year. From the current point of view, the injection in March is still effective. How long can its protection last? We are still advancing related research. At present, we can only speculate based on similar vaccines in the past. For example, the Ebola vaccine will decrease its immune response after the first injection for six months. The second needle is enhanced and can be effective for two years. This is data that can be used as a reference.

"If the new coronavirus mutates, will the vaccine fail?"

Chen Wei: We are a genetically engineered vaccine. We just find the most useful gene and make it into a vaccine. Judging from the current data analysis, the probability of a change in the gene we selected is very low. Up to now, our recombinant new coronavirus vaccine can completely cover the mutated new coronavirus.

In addition, because we are genetically engineered vaccines, once mutations occur and the protective effect is affected, we can use the current vaccines as the basic immunity, and quickly build a more targeted vaccine to boost it, just like giving Software upgrades and patches are the same. This is also the reason why so many countries in the world are making genetic engineering vaccines-it is a new generation of technology and a sunrise technology that we need to vigorously develop in the future.

"What do you think of our country's new crown vaccine development process in the world?"

Chen Wei: There is no doubt that our country is in the first phalanx of the world's new crown vaccine research and development. We currently account for more than half of the vaccines announced by the WHO that have entered phase III clinical trials. This data is already very telling.